As Donald Trump is sworn into office today, we look at what the next 100 days and indeed the next four years could mean for the biopharma industry through his recent candidates for the top healthcare roles, his policies (which are still coming into focus), and the power that 140 characters can have.
One way we biotech journalists try to gauge these things is to ask biotech CEOs, but many, including those at this year’s J.P. Morgan event, wouldn’t even mention Trump by name (“incoming administration” just about replacing He Who Shall Not Be Named), with few willing to make any predictions about his presidency, and what mark it may leave on the industry.
